Latest Pharma and Biotech News
Pharmaceutical
13 August 2025 The US Food and Drug Administration approved New Jersey, USA-based Insmed’s Brinsupri (brensocatib) tablets to treat non-cystic fibrosis bronchiectasis (NCFB), a chronic inflammatory lung condition, in patients ages 12 years and older.
Today's issue
Refine Search
Pharmaceutical
Costco has confirmed it will not sell the abortion pill mifepristone, which is sold under the Mifeprex brand, in any of its US pharmacy locations. The decision comes after pressure from faith-based advocacy groups including Alliance Defending Freedom. With Costco’s stance set, these groups are now focusing on CVS and Walgreens. 15 August 2025
Pharmaceutical
The Swiss government has met with senior executives from Roche and Novartis to discuss the outlook for the pharmaceutical industry amid escalating US trade measures. 15 August 2025
Pharmaceutical
The US Department of Health and Human Services has reinstated the Task Force on Safer Childhood Vaccines, a panel created by Congress to strengthen the safety, quality and oversight of vaccines given to American children. The original group was disbanded in 1998. 15 August 2025
Biotechnology
The US Food and Drug Administration (FDA) has approved Papzimeos (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP). 15 August 2025
Pharmaceutical
Flagship Pioneering has appointed Ajit Singh as chief executive (CEO)-partner of Flagship and the new CEO of Harbinger Health, a bioplatform Flagship company. 15 August 2025
Pharmaceutical
Swiss drug developer Basilea Pharmaceutica has entered into an exclusive license agreement with Venatorx Pharmaceuticals, to acquire the global rights to ceftibuten-ledaborbactam etzadroxil. 15 August 2025
Pharmaceutical
US pharma major Eli Lilly is raising the list price for its obesity drug Mounjaro (tirzepatide) in the UK by as much as 170%, as the pharma industry comes under pressure from US President Donald Trump to increase medicine prices in Europe and lower them for Americans. 15 August 2025
Pharmaceutical
Schrödinger has halted the clinical development of its oral drug SGR-2921 following the occurrence of two patient deaths in a Phase I dose-escalation trial. 15 August 2025
Pharmaceutical
A first-of-its-kind study from UK pharm major AstraZeneca and Macmillan Cancer Support into the barriers around access to the latest biomarker testing for cancer in the UK has been published in Future Oncology. 15 August 2025
Pharmaceutical
With help from artificial intelligence, Massachusetts Institute of Technology (MIT) researchers have designed novel antibiotics that can combat two hard-to-treat infections: drug-resistant Neisseria gonorrhoeae and multi-drug-resistant Staphylococcus aureus (MRSA). 15 August 2025
Pharmaceutical
US President Donald Trump issued an executive order on August 13 2025 instructing the Department of Health and Human Services to assemble a six-month stockpile of active pharmaceutical ingredients (APIs) for around 26 critical drugs. 15 August 2025
Pharmaceutical
Eli Lilly has entered into a collaboration with Boston-based Superluminal Medicines to develop small-molecule therapies for undisclosed G protein-coupled receptor (GPCR) targets linked to cardiometabolic diseases and obesity. 15 August 2025
Biotechnology
The UK’s National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for AstraZeneca’s Fasenra (benralizumab) for use as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). 14 August 2025
Biotechnology
Pilatus Biosciences, a US biopharmaceutical company developing novel metabolic checkpoint immunotherapies for liver and gastrointestinal cancers, today announced a clinical trial collaboration with Swiss pharma giant Roche. 14 August 2025
Biotechnology
Danish clinical-stage techbio, Evaxion, which is specializing in developing AI-Immunology powered vaccines, today provided a business update. 14 August 2025
Pharmaceutical
China-based RNA therapeutics developer Ribopeutic has raised close to 100 million yuan ($13.9 million) in pre-A financing, with Tasly Holding Group and Pan-Lin Asset Management leading the round. 14 August 2025
Pharmaceutical
Shares of Israel-based Nasus Pharma rose 7.6% to $8.88 in after-hours activity yesterday after it announced the pricing of its initial public offering of 1,250,000 ordinary shares at a public offering price of $8.00 per Ordinary Share, for aggregate gross proceeds of $10 million. 14 August 2025
Biotechnology
Maryland, USA-based biotech MacroGenics announced that effective as of August 13, 2025, Eric Risser has been appointed president, chief executive (CEO) and to the board of directors. 14 August 2025
Pharmaceutical
US biotech Response Pharmaceuticals has unveiled top-line Phase II results for its experimental obesity therapy RDX-002, aimed at helping patients maintain weight loss after discontinuing GLP-1 treatments such as Wegovy (semaglutide) and Zepbound (tirzepatide). 14 August 2025
Biotechnology
China-based RemeGen has announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, telitacicept, met the primary endpoint in its Phase III clinical trial for the treatment of primary Sjögren's syndrome (pSS) in China, as per the pre-specified study protocol. 14 August 2025
All news
Pharmaceutical
Costco has confirmed it will not sell the abortion pill mifepristone, which is sold under the Mifeprex brand, in any of its US pharmacy locations. The decision comes after pressure from faith-based advocacy groups including Alliance Defending Freedom. With Costco’s stance set, these groups are now focusing on CVS and Walgreens. 15 August 2025
Pharmaceutical
The Swiss government has met with senior executives from Roche and Novartis to discuss the outlook for the pharmaceutical industry amid escalating US trade measures. 15 August 2025
Pharmaceutical
The US Department of Health and Human Services has reinstated the Task Force on Safer Childhood Vaccines, a panel created by Congress to strengthen the safety, quality and oversight of vaccines given to American children. The original group was disbanded in 1998. 15 August 2025
Biotechnology
The US Food and Drug Administration (FDA) has approved Papzimeos (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP). 15 August 2025
Pharmaceutical
Flagship Pioneering has appointed Ajit Singh as chief executive (CEO)-partner of Flagship and the new CEO of Harbinger Health, a bioplatform Flagship company. 15 August 2025
Pharmaceutical
Swiss drug developer Basilea Pharmaceutica has entered into an exclusive license agreement with Venatorx Pharmaceuticals, to acquire the global rights to ceftibuten-ledaborbactam etzadroxil. 15 August 2025
Pharmaceutical
US pharma major Eli Lilly is raising the list price for its obesity drug Mounjaro (tirzepatide) in the UK by as much as 170%, as the pharma industry comes under pressure from US President Donald Trump to increase medicine prices in Europe and lower them for Americans. 15 August 2025
Pharmaceutical
Schrödinger has halted the clinical development of its oral drug SGR-2921 following the occurrence of two patient deaths in a Phase I dose-escalation trial. 15 August 2025
Pharmaceutical
A first-of-its-kind study from UK pharm major AstraZeneca and Macmillan Cancer Support into the barriers around access to the latest biomarker testing for cancer in the UK has been published in Future Oncology. 15 August 2025
Pharmaceutical
With help from artificial intelligence, Massachusetts Institute of Technology (MIT) researchers have designed novel antibiotics that can combat two hard-to-treat infections: drug-resistant Neisseria gonorrhoeae and multi-drug-resistant Staphylococcus aureus (MRSA). 15 August 2025
Pharmaceutical
US President Donald Trump issued an executive order on August 13 2025 instructing the Department of Health and Human Services to assemble a six-month stockpile of active pharmaceutical ingredients (APIs) for around 26 critical drugs. 15 August 2025
Pharmaceutical
Eli Lilly has entered into a collaboration with Boston-based Superluminal Medicines to develop small-molecule therapies for undisclosed G protein-coupled receptor (GPCR) targets linked to cardiometabolic diseases and obesity. 15 August 2025
Biotechnology
The UK’s National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for AstraZeneca’s Fasenra (benralizumab) for use as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). 14 August 2025
Biotechnology
Pilatus Biosciences, a US biopharmaceutical company developing novel metabolic checkpoint immunotherapies for liver and gastrointestinal cancers, today announced a clinical trial collaboration with Swiss pharma giant Roche. 14 August 2025
Biotechnology
Danish clinical-stage techbio, Evaxion, which is specializing in developing AI-Immunology powered vaccines, today provided a business update. 14 August 2025
Pharmaceutical
China-based RNA therapeutics developer Ribopeutic has raised close to 100 million yuan ($13.9 million) in pre-A financing, with Tasly Holding Group and Pan-Lin Asset Management leading the round. 14 August 2025
Pharmaceutical
Shares of Israel-based Nasus Pharma rose 7.6% to $8.88 in after-hours activity yesterday after it announced the pricing of its initial public offering of 1,250,000 ordinary shares at a public offering price of $8.00 per Ordinary Share, for aggregate gross proceeds of $10 million. 14 August 2025
Biotechnology
Maryland, USA-based biotech MacroGenics announced that effective as of August 13, 2025, Eric Risser has been appointed president, chief executive (CEO) and to the board of directors. 14 August 2025
Pharmaceutical
US biotech Response Pharmaceuticals has unveiled top-line Phase II results for its experimental obesity therapy RDX-002, aimed at helping patients maintain weight loss after discontinuing GLP-1 treatments such as Wegovy (semaglutide) and Zepbound (tirzepatide). 14 August 2025
Biotechnology
China-based RemeGen has announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, telitacicept, met the primary endpoint in its Phase III clinical trial for the treatment of primary Sjögren's syndrome (pSS) in China, as per the pre-specified study protocol. 14 August 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze